PHMD

Pharming Joenja® pediatric sNDA receives FDA Priority Review

Pharming's supplemental new drug application for lower-dose Joenja® in children aged 4+ has been accepted by the FDA with Priority Review designation, potentially expanding the addressable patient population and revenue base.